A Comparative Study of the Oxidative Profile in Graves' Disease, Hashimoto's Thyroiditis, and Papillary Thyroid Cancer
Overview
Authors
Affiliations
The aim of this study was to evaluate and compare the oxidative profiles of three thyroid disorders: Graves' disease (GD), Hashimoto thyroiditis (HT), and papillary thyroid cancer (PTC). Malondialdehyde levels (MDA), glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT) activities were examined in the plasma of 52 patients (29 untreated HT, 16 untreated GD, and 7 PTC who underwent surgical therapy). Results were compared with those of 30 healthy controls and among the three groups of patients. The GD, HT, and PTC patients exhibited increased plasma MDA levels and SOD activities compared with the controls (p < 0.05, p < 0.05, and p < 0.001, respectively). CAT activities significantly increased only for the PTC and HT patients (p < 0.001 and p < 0.05, respectively), whereas GPx activities significantly decreased only in the GD and PTC (p < 0.05 and p < 0.01, respectively). The comparison among the three groups of patients has shown increased MDA level and SOD activity for the PTC patients as compared to the GD patients (p < 0.01 and p < 0.001, respectively). Compared with HT, PTC patients exhibited significant higher MDA level, SOD, and CAT activities and a significant lower GPx activity (p < 0.01, p < 0.001, p < 0.05, and p < 0.05, respectively). No significant discrepancies were noted between the GD and HT patients. Our results have clearly shown an oxidative profile that is highly disturbed for the PTC patients as compared to those of autoimmune disorders. Future studies are needed to determine whether or not the oxidative stress has a prognostic value in this pathology.
Hypothyroid women have persistently higher oxidative stress compared to healthy controls.
Riis K, Larsen C, Medici B, Jensen C, Winther K, Larsen E Eur Thyroid J. 2023; 12(6).
PMID: 37855410 PMC: 10692686. DOI: 10.1530/ETJ-23-0167.
The protective role of nutritional antioxidants against oxidative stress in thyroid disorders.
Macvanin M, Gluvic Z, Zafirovic S, Gao X, Essack M, Isenovic E Front Endocrinol (Lausanne). 2023; 13:1092837.
PMID: 36686463 PMC: 9846570. DOI: 10.3389/fendo.2022.1092837.
Xu H, Hu X, Li J, Nie Z, Kang S, Liu H Biol Trace Elem Res. 2022; 201(7):3279-3289.
PMID: 36227448 DOI: 10.1007/s12011-022-03448-4.
Unraveling the Effects of Carotenoids Accumulation in Human Papillary Thyroid Carcinoma.
Di Masi A, Sessa R, Cerrato Y, Pastore G, Guantario B, Ambra R Antioxidants (Basel). 2022; 11(8).
PMID: 36009182 PMC: 9405418. DOI: 10.3390/antiox11081463.
Lopes N, Lens H, da Silva Brito W, Bianchi J, Marinello P, Cecchini R Clin Transl Oncol. 2022; 24(12):2366-2378.
PMID: 35902455 DOI: 10.1007/s12094-022-02891-y.